Varian Associates of Palo Alto, CA, this month finalized its restructuring into three independent public companies when it began trading shares in its instruments and semiconductor equipment firms. On April 2, Varian and Varian Semiconductor
Varian Associates of Palo Alto, CA, this month finalized its restructuring into three independent public companies when it began trading shares in its instruments and semiconductor equipment firms. On April 2, Varian and Varian Semiconductor Equipment Associates commenced trading on NASDAQ. Varian Associates, which will be renamed Varian Medical Systems, continues to trade on the New York Stock Exchange. Varians board of directors proposed splitting the company in August of last year, and shareholders voted agreement in February (SCAN 3/3/99).
© 1999 Miller Freeman, Inc.All rights reserved.
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.
Can MRI-Based AI Enhance Pre-Op Prediction of Tumor Deposits in Patients with Rectal Cancer?
October 31st 2024For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.
Artifact Reduction Drives Technology Advances with Updated Version of Echelon Synergy MRI System
October 30th 2024Emerging technologies included with the 10th version of the 1.5T MRI platform include Synergy DLR Clear and Synergy Vision that are geared toward mitigating common challenges with artifacts.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).